Meta-Analysis: Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia

Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials – Journal of the American Heart Association (free)

PCSK9 inhibitors were associated with reduced incidence of myocardial infarction (2.3% vs 3,6%), stroke (1.0% vs 1.4%) and coronary revascularization (4,2% vs 5,8%). Overall, no significant change was observed in cardiovascular or all-cause mortality.